Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.35 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7069483 | 0.91 | NPSR1 (0.41) | NPSR1CNR2KMT2ATAS2R14ADAMTS5 | |
| SCHEMBL7314567 | 0.85 | CYP2D6 (0.34) | NPSR1L3MBTL1ALDH1A1 | |
| SCHEMBL3870277 | 0.81 | PTGES (0.35) | NPSR1LMNAMEN1KMT2AADAMTS5 | |
| SCHEMBL3870123 | 0.81 | P2RX7 (0.36) | NPSR1CNR2LMNAMEN1KMT2A | |
| SCHEMBL7645512 | 0.80 | PPARG (0.34) | NPSR1CNR2LMNAMEN1KMT2A | |
| SCHEMBL3877158 | 0.80 | P2RX7 (0.32) | CNR2LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL3870071 | 0.79 | P2RX7 (0.32) | LMNAMEN1KMT2AALDH1A1GAA | |
| SCHEMBL3870515 | 0.79 | P2RX7 (0.34) | LMNAMEN1KMT2AALDH1A1GAA | |
| SCHEMBL5691489 | 0.79 | ENPP3 (0.36) | POLBLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL7327485 | 0.78 | HRH1 (0.36) | NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030065193-A1 | Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-04-03 | — | — | US | claimed |
| US-6362341-B1 | ANTIINFLAMMATORY AGENTS | ATHENA NEUROSCIENCES, INC. | 2002-03-26 | — | — | US | claimed |
| EP-1001975-A1 | BENZYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-24 | — | — | EP | claimed |
| WO-1999006436-A1 | BENZYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | claimed |
| US-6586602-B2 | CD antigen antagonists such as N-(methanesulfonyl)-L-prolyl-L-phenylalanine and prodrugs used as antiinflammatory agents | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-07-01 | — | — | US | disclosed |
| US-20030065193-A1 | Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-04-03 | — | — | US | disclosed |
| US-6362341-B1 | ANTIINFLAMMATORY AGENTS | ATHENA NEUROSCIENCES, INC. | 2002-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065193-A1 | Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | POLB 3878/4885NPSR1 2315/4885L3MBTL1 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.